12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pasireotide: Phase III data

A double-blind, international Phase III trial in patients with acromegaly showed that pasireotide met the primary endpoint of a significantly greater proportion of patients achieving a reduction in mean...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >